At least 25,000 people in the US are starting weight-loss drug Wegovy each week, drugmaker says

Novo Nordisk reports that 25,000 Americans start using its weight-loss drug Wegovy weekly, a significant increase from December. Amid high demand, Novo Nordisk and competitor Eli Lilly are expanding manufacturing to address shortages and improve access, despite challenges with insurance coverage for weight-loss drugs. Wegovy, approved for weight loss in 2021, also shows potential cardiovascular benefits, which could further increase demand and improve insurance coverage.